Camp4 gains after earning bullish views on Street

aluxum Recently IPO'ed biotech Camp4 Therapeutics ( NASDAQ: CAMP ) recorded its best intraday gains since its public debut in October as J.P. Morgan and Piper Sandler launched its coverage with Overweight recommendations.

J.P. Morgan analyst Eric Joseph issued a $23 per share target for the.